Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

• Sponsor: GlaxoSmithKline (Industry)
• Overall Status: Terminated
• CT.gov ID: NCT01978236
• Collaborator: (none)
• Enrollment: 6
• Locations: 3
• Arms: 2
• Actual Duration (Months): 36.6
• Patients Per Site: 2
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This is a global, multi-centre, open-label, study of GSK2118436 conducted in up to 30 evaluable subjects with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. All subjects in this study are required to have accessible extracranial metastases and are agreeable to undergo repetitive biopsies. The first cohort of 15 subjects will receive dabrafenib orally 150mg twice daily (BID) for 7 to 14 days prior to surgery (Cohort A); the second cohort of 15 subjects will receive the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily for 7 to 14 days prior to surgery (Cohort B). The primary purpose of this study is to determine levels and distribution of dabrafenib, its metabolites, and trametinib (Cohort B only) in parenchymal brain metastases, extracranial metastases, and peripheral blood (plasma) within two cohorts of subjects with BRAF V600E/K mutation-positive melanoma that has metastasized to the brain. All subjects will be followed for survival and new anti-cancer therapy for a total of two years or until death or the subject wishes to withdraw from further follow-up.

Condition or Disease	Intervention/Treatment	Phase
Melanoma and Brain Metastases	Drug: Dabrafenib 150 mg; Drug: Trametinib 2.0 mg	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 6 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
• Actual Study Start Date: Apr 8, 2014
• Actual Primary Completion Date: Apr 26, 2017
• Actual Study Completion Date: Apr 26, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort A The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery	Drug: Dabrafenib 150 mg; Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
Experimental: Cohort B The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery	Drug: Dabrafenib 150 mg; Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.; Drug: Trametinib 2.0 mg; Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.

Outcome Measures

Primary Outcome Measures

1. Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Peripheral Blood (Plasma) [Pre-surgery and post-surgery on Day 15]

   Blood samples for pharmacokinetic analysis of dabrafenib and its active metabolites, including hydroxy-, carboxy-, and desmethyl-dabrafenib were collected on day of surgical resection of the brain metastasis(es), Two samples were collected before surgery and 2 samples after surgery with one hour gap in between. Upon collection blood was placed on wet ice. Plasma was isolated within 60 minutes of collection and frozen at -20 degree celsius.

2. Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Parenchymal Brain Metastases [Day 15]

   Concentrations of dabrafenib, its metabolites, hydroxy-, carboxy, and desmethyl-dabrafenib, and possibly other drug-related species were quantified in the pharmacokinetic tissue sample by an investigative Liquid chromatography- mass spectrometry (LC-MS)/MS method. The spatial distribution of dabrafenib, its metabolites, hydroxy-, carboxy, and desmethyl-dabrafenib and possibly other drug-related species in the tissue samples were determined using an investigative matrix assisted laser desorption ionization (MALDI) analysis method. Parenchymal brain metastases and extracranial metastases using MALDI imaging was not determined for all participants (completed by GSK for the first two participants enrolled)

3. Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) and Trametinib (Cohort B Only) in CSF Samples. [Pre-surgery and post-surgery on Day 15]

   Blood samples for pharmacokinetic analysis of dabrafenib and its active metabolites, including hydroxy-, carboxy-, and desmethyl-dabrafenib and trametinib (as appropriate), were planned but not collected.

Secondary Outcome Measures

1. Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) in Cerebrospinal Fluid (CSF) Samples [Day 15]

   Concentrations of dabrafenib, its metabolites hydroxy-, carboxy- and desmethyl-dabrafenib) and trametinib in CSF (in participants who agree for optional collection of CSF at the time of brain tumor resection). Optional collection of CSF was obtained in the operating room on the day of brain metastasis resection. CSF samples for only one participant were collected and analyzed.

2. Number of Participants With Changes in Mitogen-activated Protein Kinase (MAPK) Pathway Markers [Up to Day 15]

   Changes in MAPK pathway markers in paired extracranial biopsies taken pre-treatment, during craniotomy, and at disease progression, and changes in markers between post-operative intracranial and extracranial biopsies was planned but not performed as the study was terminated due to low enrollment.

3. Number of Participants With Changes in Radiographic Tumors [Up to 2 years]

   Changes in the radiographic characteristics of the tumors were planned to be compared to (1) levels of dabrafenib, its metabolites and trametinib (where appropriate) in the brain metastases, plasma, and CSF, and (2) MAPK pathway activation status in tumors at the time of surgery. Results were planned to be compared to the analysis of early clinical responses in extracranial metastases, as determined by the Positron emission tomography (PET-CT) imaging. This analysis was planned but not performed as the study was terminated due to low enrollment

4. Percent Change From Baseline to Pre-surgery in the Sum of the Longest Diameters (SLD) of Intracranial Target Lesions [Up to 2 years]

   The change from Baseline to the pre-surgery intracranial disease assessment in the SLD of intracranial target lesions was planned to be calculated as a percentage change from the baseline SLD. It was planned to be reported for the V600E and V600K analysis populations for each cohort and also aggregately if appropriate. This analysis was planned but not performed as the study was terminated due to low enrollment.

5. Maximum Percent Change From Baseline in the SLD of Unresected Intracranial Target Lesions [Up to 2 years]

   The maximum change from Baseline in the SLD of unresected intracranial target lesions was planned to be calculated as a percentage change from the baseline SLD. It was planned to be reported for the V600E and V600K analysis populations for each cohort and also aggregately if appropriate. This analysis was planned but not performed as the study was terminated due to low enrollment.

6. Percentage of Participants With Overall Extracranial Response Rate in Unresected Lesions [Approximately 2 years or death whichever occurs first]

   Overall Extracranial Response Rate was defined as the percentage of participants with Complete response (CR) or Partial response (PR) at anytime as per modified Response Evaluation Criteria in Solid Tumors (RECIST). The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence and is determined programmatically based on the investigator's assessment of response at each time point. Overall Extracranial Response Rate was planned but not analyzed as the study was terminated due to low enrollment.

7. Percentage of Participants With Overall Survival [Approximately 2 years or death whichever occurs first]

   Overall survival, defined as the time from first dose of study treatment to death for any reason, was planned to summarize using Kaplan-Meier quartile estimates along with two sided 95% confidence intervals. But were not performed as the study was terminated due to low enrollment.

8. Number of Participants With Abnormal Vital Signs [Up to 2 years]

   Vital sign measurements including temperature, respiratory rate, systolic and diastolic blood pressure, and pulse rate were planned to be performed but were neither summarized nor listed as the study was terminated.

9. Number of Participants With Abnormal Physical Examinations [Up to 2 years]

   A complete physical examination was planned which included assessments of the head, eyes, ears, nose, throat, skin, thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities. Height and weight was also planned to be measured and recorded. A complete physical exam including a thorough genitourinary examination for female participants, inspection of the head and neck region, and digital rectal examination for both male and female participants was planned to be performed at Screening, and Month 12 or at discontinuation if discontinuation occurs prior to Month 12. If the participants had a genitourinary and rectal exam within 6 months of screening, these assessments need not to be repeated at screening. But data for physical examinations were not summarized and listed as the study was terminated.

10. Number of Participants With Abnormal 12-lead Electrocardiograms (ECG) [Screening]

    112-lead ECGs were planned to be obtained at screening during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. At each assessment a 12-lead ECG was planned to be performed by qualified personnel at the site after at least a five-minute rest with the participants in a semi-recumbent or supine position. But data for 12-lead ECGs were not summarized and listed as the study was terminated.

11. Number of Participants With Abnormal Echocardiogram (ECHO) [Up to 2 years]

    ECHO include an evaluation for Left ventricular ejection fraction (LVEF) and both right- and left-sided valvular lesions. ECHO was planned to be performed at screening, Week 8 and every 16 weeks till discontinuation. data for ECHO was not summarized and listed as the study was terminated.

12. Number of Participants With Abnormal Clinical Laboratory Assessments [Up to 2 years]

    Laboratory assessments included parameters like Hematology, Standard Chemistry, Coagulation, Serum Pregnancy. Assessment of these parameters were planned to be performed by the central laboratory on screening, Day prior to surgery, Every 4 weeks after restart and Discontinuation, but were not analyzed as the study was terminated due to low enrollment.

13. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) [Up to 2 years]

    AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE were collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy using Medical Dictionary for Regulatory Activities (MedDRA)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Signed written informed consent

• Histologically-confirmed metastatic melanoma (Stage IV), carrying BRAF V600E or V600K mutation as determined by testing certified for clinical diagnostic purposes. Previously performed certified BRAF testing is acceptable. If no prior BRAF mutation testing results are available, testing of a distant metastasis is preferred, but testing of a regional metastasis or primary tumor is also acceptable

• At least one intracranial lesion >=1.0 cm but <=4.0 cm that can be treated with surgical resection in the opinion of the treating physicians, and for which immediate local therapy is not clinically indicated

• At least two extracranial lesions that are easily accessible for biopsy, in the judgment of the treating physician. Easily accessible tumors may include cutaneous, subcutaneous, and superficial lymph node metastases.

• Age >18 years of age.

• Able to swallow and retain oral medication

• Women with child-bearing potential must be willing to practice acceptable methods of birth control during the study

• Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment.

• Must be able to understand and comply with protocol requirements and instructions

• Eastern Co-operative Oncology Group (ECOG) performance status of 0-2

• Must have adequate organ function as defined by the following screening values (Retesting of borderline screening organ function and treatment with blood transfusions, growth factors etc. will be allowed):

• Absolute neutrophil count (ANC) >=1.2x10^9/L

• Hemoglobin >=9 g/dL

• Platelets >=100x10^9/L

• Serum bilirubin <=1.5 x upper limit of normal (ULN)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5xULN

• Serum creatinine <=1.5 mg/dL (If serum creatinine is >1.5 mg/dL, calculate creatinine clearance using standard Cockcroft and Gault Method Creatinine clearance must be >50 mL/min)

• Prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) <=1.3xULN

• Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN)

Exclusion Criteria:

• Neurological symptoms related to brain metastasis that are not controlled with a stable or decreasing dose of oral steroids for at least 7 days prior to starting GSK2118436

• Prior Central Nervous System (CNS)-directed local therapies, including surgical resection, whole brain radiation (WBRT), Stereotactic radiosurgery (SRS), or gamma knife (GK)

• Previous treatment with a BRAF or MEK inhibitor

• Cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks, preceding the first dose of study treatment.

• Current or expected use of a prohibited medication, including enzyme-inducing antiepileptic drugs (EIAEDs) during treatment with GSK2118436.

• Presence of leptomeningeal disease or dural metastases.

• History of another active malignancy within the past 5 years, or any malignancy with a confirmed activating RAS mutation. The prospective RAS mutation testing is not required, however, if results of previous RAS testing are known, they must be used in assessing eligibility. Subjects with a history of completely resected non-melanoma skin cancer are eligible.

• Known allergies against contrast agents required for magnetic resonance imaging (MRI) of intracranial lesions, or other contraindications for MRI, i.e., pacemaker

• Current use of therapeutic warfarin. Low-molecular-weight heparin and prophylactic low-dose warfarin are permitted

• Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia

• Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.

• History of a prior symptomatic stroke, dementia, or other significant central neurologic condition (i.e. multiple sclerosis)

• A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection

• Current acute infection requiring intravenous antibiotics

• A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency

• The history or evidence of following cardiac abnormalities:

• Corrected QT (QTc) interval using Bazett's Formula; (QTcB) >= 480 msecs

• A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization

• Coronary angioplasty or stenting within the past 12 weeks

• Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system

• Abnormal cardiac valve morphology (>= Grade 2) documented by echocardiogram (ECHO)

• History of or evidence of clinically significant uncontrolled cardiac arrhythmias

• Treatment refractory hypertension defined as a blood pressure of systolic >140 mmHg and/or diastolic >90 mm Hg which cannot be controlled by anti-hypertensive therapy

• Subjects with intra-cardiac defibrillators or permanent pacemakers

• Pregnant, lactating or breastfeeding females

• Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures

• Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2118436 or excipients that contraindicate their participation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Pittsburgh	Pennsylvania	United States	15232
2	GSK Investigational Site	Houston	Texas	United States	77030
3	GSK Investigational Site	North Sydney	New South Wales	Australia	2060

Sponsors and Collaborators

• GlaxoSmithKline

Investigators

• Study Director: GSK Clinical Trials, GlaxoSmithKline

Study Documents (Full-Text)

• Study Protocol - Apr 15, 2015
• Statistical Analysis Plan - Apr 8, 2017

More Information

Publications

None provided.

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT01978236
• Other Study ID Numbers: 116521
• First Posted: Nov 7, 2013
• Last Update Posted: Aug 17, 2018
• Last Verified: Jul 1, 2018

• Keywords provided by GlaxoSmithKline: BRAF V600E mutation; brain metastases; BRAF V600K mutation; Metastatic melanoma; BRAF inhibitor; brain neoplasms; GSK2118436
• Additional relevant MeSH terms: Melanoma; Neoplasm Metastasis; Brain Neoplasms; Trametinib; Dabrafenib

Study Results

Participant Flow

Recruitment Details	Six participants (five male and one female) with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain were enrolled into the study, all into Cohort A. There were no participants enrolled in Cohort B.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Period Title: Overall Study
STARTED	6
COMPLETED	4
NOT COMPLETED	2

Baseline Characteristics

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Overall Participants	6
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	56.2 (16.52)
Sex: Female, Male (Count of Participants)
Female	1 16.7%
Male	5 83.3%
Race/Ethnicity, Customized (Count of Participants)
White - Arabic/North African Heritage	1 16.7%
White/Caucasian/European Heritage	5 83.3%

Outcome Measures

1. Primary Outcome

Title	Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Peripheral Blood (Plasma)
Description	Blood samples for pharmacokinetic analysis of dabrafenib and its active metabolites, including hydroxy-, carboxy-, and desmethyl-dabrafenib were collected on day of surgical resection of the brain metastasis(es), Two samples were collected before surgery and 2 samples after surgery with one hour gap in between. Upon collection blood was placed on wet ice. Plasma was isolated within 60 minutes of collection and frozen at -20 degree celsius.
Time Frame	Pre-surgery and post-surgery on Day 15

Outcome Measure Data

Analysis Population Description

The Pharmacokinetic analysis set included all participants who provided at least one evaluable Pharmacokinetic concentration.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	6
Participant 1, Dabrafenib, Pre-Surgery 1	2.54
Participant 1, Dabrafenib, Pre-Surgery 2	2.66
Participant 1, Dabrafenib, Post-Surgery 1	1.24
Participant 1, Dabrafenib, Post-Surgery 2	1.32
Participant 1, Desmethyl-dabrafenib,Pre-Surgery 1	357
Participant 1, Desmethyl-dabrafenib,Pre-Surgery 2	438
Participant 1, Desmethyl-dabrafenib,Post-Surgery 1	153
Participant 1, Desmethyl-dabrafenib,Post-Surgery 2	147
Participant 1,Hydroxy-dabrafenib,Pre-Surgery 1	4.72
Participant 1,Hydroxy-dabrafenib,Pre-Surgery 2	4.91
Participant 1,Hydroxy-dabrafenib,Post-Surgery 1	1.66
Participant 1,Hydroxy-dabrafenib,Post-Surgery 2	1.58
Participant 1,carboxy-dabrafenib,Pre-Surgery 1	694
Participant 1,carboxy-dabrafenib,Pre-Surgery 2	621
Participant 1,carboxy-dabrafenib,Post-Surgery 1	454
Participant 1,carboxy-dabrafenib,Post-Surgery 2	423
Participant 2, Dabrafenib, Pre-Surgery 1	953
Participant 2, Dabrafenib, Pre-Surgery 2	596
Participant 2, Dabrafenib, Post-Surgery 1	137
Participant 2, Dabrafenib, Post-Surgery 2	119
Participant 2, Desmethyl-dabrafenib,Pre-Surgery 1	150
Participant 2, Desmethyl-dabrafenib,Pre-Surgery 2	180
Participant 2, Desmethyl-dabrafenib,Post-Surgery 1	90.1
Participant 2, Desmethyl-dabrafenib,Post-Surgery 2	79.1
Participant 2,Hydroxy-dabrafenib,Pre-Surgery 1	644
Participant 2,Hydroxy-dabrafenib,Pre-Surgery 2	507
Participant 2,Hydroxy-dabrafenib,Post-Surgery 1	102
Participant 2,Hydroxy-dabrafenib,Post-Surgery 2	101
Participant 2,carboxy-dabrafenib,Pre-Surgery 1	2010
Participant 2,carboxy-dabrafenib,Pre-Surgery 2	3020
Participant 2,carboxy-dabrafenib,Post-Surgery 1	2150
Participant 2,carboxy-dabrafenib,Post-Surgery 2	2040
Participant 3, Dabrafenib, Pre-Surgery 1	151
Participant 3, Dabrafenib, Pre-Surgery 2	127
Participant 3, Dabrafenib, Post-Surgery 1	18.2
Participant 3, Dabrafenib, Post-Surgery 2	12.6
Participant 3, Desmethyl-dabrafenib,Pre-Surgery 1	532
Participant 3, Desmethyl-dabrafenib,Pre-Surgery 2	656
Participant 3, Desmethyl-dabrafenib,Post-Surgery 1	295
Participant 3, Desmethyl-dabrafenib,Post-Surgery 2	238
Participant 3,Hydroxy-dabrafenib,Pre-Surgery 1	215
Participant 3,Hydroxy-dabrafenib,Pre-Surgery 2	182
Participant 3,Hydroxy-dabrafenib,Post-Surgery 1	36.2
Participant 3,Hydroxy-dabrafenib,Post-Surgery 2	24.9
Participant 3,carboxy-dabrafenib,Pre-Surgery 1	4360
Participant 3,carboxy-dabrafenib,Pre-Surgery 2	4300
Participant 3,carboxy-dabrafenib,Post-Surgery 1	2620
Participant 3,carboxy-dabrafenib,Post-Surgery 2	2570
Participant 4, Dabrafenib, Pre-Surgery 1	134
Participant 4, Dabrafenib, Pre-Surgery 2	111
Participant 4, Dabrafenib, Post-Surgery 1	10.2
Participant 4, Dabrafenib, Post-Surgery 2	6.84
Participant 4, Desmethyl-dabrafenib,Pre-Surgery 1	896
Participant 4, Desmethyl-dabrafenib,Pre-Surgery 2	961
Participant 4, Desmethyl-dabrafenib,Post-Surgery 1	377
Participant 4, Desmethyl-dabrafenib,Post-Surgery 2	286
Participant 4,Hydroxy-dabrafenib,Pre-Surgery 1	106
Participant 4,Hydroxy-dabrafenib,Pre-Surgery 2	86.1
Participant 4,Hydroxy-dabrafenib,Post-Surgery 1	13.7
Participant 4,Hydroxy-dabrafenib,Post-Surgery 2	9.54
Participant 4,carboxy-dabrafenib,Pre-Surgery 1	1390
Participant 4,carboxy-dabrafenib,Pre-Surgery 2	1380
Participant 4,carboxy-dabrafenib,Post-Surgery 1	865
Participant 4,carboxy-dabrafenib,Post-Surgery 2	620
Participant 5, Dabrafenib, Pre-Surgery 1	101
Participant 5, Dabrafenib, Pre-Surgery 2	51.1
Participant 5, Dabrafenib, Post-Surgery 1	15.4
Participant 5, Dabrafenib, Post-Surgery 2	11
Participant 5, Desmethyl-dabrafenib,Pre-Surgery 1	661
Participant 5, Desmethyl-dabrafenib,Pre-Surgery 2	420
Participant 5, Desmethyl-dabrafenib,Post-Surgery 1	433
Participant 5, Desmethyl-dabrafenib,Post-Surgery 2	386
Participant 5,Hydroxy-dabrafenib,Pre-Surgery 1	312
Participant 5,Hydroxy-dabrafenib,Pre-Surgery 2	183
Participant 5,Hydroxy-dabrafenib,Post-Surgery 1	62.5
Participant 5,Hydroxy-dabrafenib,Post-Surgery 2	52.4
Participant 5,carboxy-dabrafenib,Pre-Surgery 1	4580
Participant 5,carboxy-dabrafenib,Pre-Surgery 2	3750
Participant 5,carboxy-dabrafenib,Post-Surgery 1	2770
Participant 5,carboxy-dabrafenib,Post-Surgery 2	2550
Participant 6, Dabrafenib, Pre-Surgery 1	176
Participant 6, Dabrafenib, Pre-Surgery 2	106
Participant 6, Dabrafenib, Post-Surgery 1	83.2
Participant 6, Dabrafenib, Post-Surgery 2	61.4
Participant 6, Desmethyl-dabrafenib,Pre-Surgery 1	1530
Participant 6, Desmethyl-dabrafenib,Pre-Surgery 2	1050
Participant 6, Desmethyl-dabrafenib,Post-Surgery 1	1310
Participant 6, Desmethyl-dabrafenib,Post-Surgery 2	1200
Participant 6,Hydroxy-dabrafenib,Pre-Surgery 1	326
Participant 6,Hydroxy-dabrafenib,Pre-Surgery 2	227
Participant 6,Hydroxy-dabrafenib,Post-Surgery 1	197
Participant 6,Hydroxy-dabrafenib,Post-Surgery 2	151
Participant 6,carboxy-dabrafenib,Pre-Surgery 1	2680
Participant 6,carboxy-dabrafenib,Pre-Surgery 2	2250
Participant 6,carboxy-dabrafenib,Post-Surgery 1	2170
Participant 6,carboxy-dabrafenib,Post-Surgery 2	2410

2. Primary Outcome

Title	Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Parenchymal Brain Metastases
Description	Concentrations of dabrafenib, its metabolites, hydroxy-, carboxy, and desmethyl-dabrafenib, and possibly other drug-related species were quantified in the pharmacokinetic tissue sample by an investigative Liquid chromatography- mass spectrometry (LC-MS)/MS method. The spatial distribution of dabrafenib, its metabolites, hydroxy-, carboxy, and desmethyl-dabrafenib and possibly other drug-related species in the tissue samples were determined using an investigative matrix assisted laser desorption ionization (MALDI) analysis method. Parenchymal brain metastases and extracranial metastases using MALDI imaging was not determined for all participants (completed by GSK for the first two participants enrolled)
Time Frame	Day 15

Outcome Measure Data

Analysis Population Description

Pharmacokinetic Analysis Set

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	6
Participant 1,Dabrafenib	0
: Participant 1, Hydroxy-dabrafenib	0
Participant 1, Carboxy-dabrafenib	131
Participant 1, Desmethyl-dabrafenib	60
Participant 2,Dabrafenib	57.0
Participant 2, Hydroxy-dabrafenib	16.0
Participant 2, Carboxy-dabrafenib	81.0
Participant 2, Desmethyl-dabrafenib	15.0
Participant 3,Dabrafenib	40.5
Participant 3, Hydroxy-dabrafenib	63.7
Participant 3, Carboxy-dabrafenib	628
Participant 3, Desmethyl-dabrafenib	53.4
Participant 4,Dabrafenib	0
Participant 4, Hydroxy-dabrafenib	0
Participant 4, Carboxy-dabrafenib	228
Participant 4, Desmethyl-dabrafenib	88.4
Participant 5,Dabrafenib	22.5
Participant 5, Hydroxy-dabrafenib	94.3
Participant 5, Carboxy-dabrafenib	898
Participant 5, Desmethyl-dabrafenib	82.3
Participant 6,Dabrafenib	124
Participant 6, Hydroxy-dabrafenib	261
Participant 6, Carboxy-dabrafenib	660
Participant 6, Desmethyl-dabrafenib	197

3. Primary Outcome

Title	Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) and Trametinib (Cohort B Only) in CSF Samples.
Description	Blood samples for pharmacokinetic analysis of dabrafenib and its active metabolites, including hydroxy-, carboxy-, and desmethyl-dabrafenib and trametinib (as appropriate), were planned but not collected.
Time Frame	Pre-surgery and post-surgery on Day 15

Outcome Measure Data

Analysis Population Description

Pharmacokinetic Analysis Set

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

4. Secondary Outcome

Title	Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) in Cerebrospinal Fluid (CSF) Samples
Description	Concentrations of dabrafenib, its metabolites hydroxy-, carboxy- and desmethyl-dabrafenib) and trametinib in CSF (in participants who agree for optional collection of CSF at the time of brain tumor resection). Optional collection of CSF was obtained in the operating room on the day of brain metastasis resection. CSF samples for only one participant were collected and analyzed.
Time Frame	Day 15

Outcome Measure Data

Analysis Population Description

Pharmacokinetic Analysis Set

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	1
Dabrafenib	0.00
Desmethyl-dabrafenib	2.30
Hydroxy-dabrafenib	2.26
Carboxy-dabrafenib	36.9

5. Secondary Outcome

Title	Number of Participants With Changes in Mitogen-activated Protein Kinase (MAPK) Pathway Markers
Description	Changes in MAPK pathway markers in paired extracranial biopsies taken pre-treatment, during craniotomy, and at disease progression, and changes in markers between post-operative intracranial and extracranial biopsies was planned but not performed as the study was terminated due to low enrollment.
Time Frame	Up to Day 15

Outcome Measure Data

Analysis Population Description

Full Analysis Set. Analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

6. Secondary Outcome

Title	Number of Participants With Changes in Radiographic Tumors
Description	Changes in the radiographic characteristics of the tumors were planned to be compared to (1) levels of dabrafenib, its metabolites and trametinib (where appropriate) in the brain metastases, plasma, and CSF, and (2) MAPK pathway activation status in tumors at the time of surgery. Results were planned to be compared to the analysis of early clinical responses in extracranial metastases, as determined by the Positron emission tomography (PET-CT) imaging. This analysis was planned but not performed as the study was terminated due to low enrollment
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Full Analysis Set. Analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

7. Secondary Outcome

Title	Percent Change From Baseline to Pre-surgery in the Sum of the Longest Diameters (SLD) of Intracranial Target Lesions
Description	The change from Baseline to the pre-surgery intracranial disease assessment in the SLD of intracranial target lesions was planned to be calculated as a percentage change from the baseline SLD. It was planned to be reported for the V600E and V600K analysis populations for each cohort and also aggregately if appropriate. This analysis was planned but not performed as the study was terminated due to low enrollment.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

8. Secondary Outcome

Title	Maximum Percent Change From Baseline in the SLD of Unresected Intracranial Target Lesions
Description	The maximum change from Baseline in the SLD of unresected intracranial target lesions was planned to be calculated as a percentage change from the baseline SLD. It was planned to be reported for the V600E and V600K analysis populations for each cohort and also aggregately if appropriate. This analysis was planned but not performed as the study was terminated due to low enrollment.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

9. Secondary Outcome

Title	Percentage of Participants With Overall Extracranial Response Rate in Unresected Lesions
Description	Overall Extracranial Response Rate was defined as the percentage of participants with Complete response (CR) or Partial response (PR) at anytime as per modified Response Evaluation Criteria in Solid Tumors (RECIST). The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence and is determined programmatically based on the investigator's assessment of response at each time point. Overall Extracranial Response Rate was planned but not analyzed as the study was terminated due to low enrollment.
Time Frame	Approximately 2 years or death whichever occurs first

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

10. Secondary Outcome

Title	Percentage of Participants With Overall Survival
Description	Overall survival, defined as the time from first dose of study treatment to death for any reason, was planned to summarize using Kaplan-Meier quartile estimates along with two sided 95% confidence intervals. But were not performed as the study was terminated due to low enrollment.
Time Frame	Approximately 2 years or death whichever occurs first

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

11. Secondary Outcome

Title	Number of Participants With Abnormal Vital Signs
Description	Vital sign measurements including temperature, respiratory rate, systolic and diastolic blood pressure, and pulse rate were planned to be performed but were neither summarized nor listed as the study was terminated.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

12. Secondary Outcome

Title	Number of Participants With Abnormal Physical Examinations
Description	A complete physical examination was planned which included assessments of the head, eyes, ears, nose, throat, skin, thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities. Height and weight was also planned to be measured and recorded. A complete physical exam including a thorough genitourinary examination for female participants, inspection of the head and neck region, and digital rectal examination for both male and female participants was planned to be performed at Screening, and Month 12 or at discontinuation if discontinuation occurs prior to Month 12. If the participants had a genitourinary and rectal exam within 6 months of screening, these assessments need not to be repeated at screening. But data for physical examinations were not summarized and listed as the study was terminated.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

13. Secondary Outcome

Title	Number of Participants With Abnormal 12-lead Electrocardiograms (ECG)
Description	112-lead ECGs were planned to be obtained at screening during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. At each assessment a 12-lead ECG was planned to be performed by qualified personnel at the site after at least a five-minute rest with the participants in a semi-recumbent or supine position. But data for 12-lead ECGs were not summarized and listed as the study was terminated.
Time Frame	Screening

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

14. Secondary Outcome

Title	Number of Participants With Abnormal Echocardiogram (ECHO)
Description	ECHO include an evaluation for Left ventricular ejection fraction (LVEF) and both right- and left-sided valvular lesions. ECHO was planned to be performed at screening, Week 8 and every 16 weeks till discontinuation. data for ECHO was not summarized and listed as the study was terminated.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

15. Secondary Outcome

Title	Number of Participants With Abnormal Clinical Laboratory Assessments
Description	Laboratory assessments included parameters like Hematology, Standard Chemistry, Coagulation, Serum Pregnancy. Assessment of these parameters were planned to be performed by the central laboratory on screening, Day prior to surgery, Every 4 weeks after restart and Discontinuation, but were not analyzed as the study was terminated due to low enrollment.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Full Analysis Set. This analysis was planned but not performed as the study was terminated due to low enrollment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	0

16. Secondary Outcome

Title	Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
Description	AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE were collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy using Medical Dictionary for Regulatory Activities (MedDRA)
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Safety Set Population The Safety Set comprised of all participants who received at least one dose of study treatment.

Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
Measure Participants	6
Any AE	6 100%
Any SAE	4 66.7%

Adverse Events

Time Frame	On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment up to 2 years
Adverse Event Reporting Description	AEs and SAEs were collected in Safety Set Population which comprised of all participants who received at least one dose of study treatment.
Arm/Group Title	Cohort A
Arm/Group Description	Participants in Cohort A received dabrafenib orally 150 milligram twice daily for 7 to 14 days prior to surgery.
All Cause Mortality
	Cohort A
	Affected / at Risk (%)	# Events
Total	4/6 (66.7%)
Serious Adverse Events
	Cohort A
	Affected / at Risk (%)	# Events
Total	4/6 (66.7%)
Gastrointestinal disorders
Nausea	2/6 (33.3%)
Dysphagia	1/6 (16.7%)
Vomiting	1/6 (16.7%)
General disorders
Chills	1/6 (16.7%)
Pyrexia	1/6 (16.7%)
Hepatobiliary disorders
Granulomatous liver disease	1/6 (16.7%)
Metabolism and nutrition disorders
Dehydration	1/6 (16.7%)
Nervous system disorders
Dizziness	1/6 (16.7%)
Headache	1/6 (16.7%)
Psychiatric disorders
Confusional state	1/6 (16.7%)
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease	1/6 (16.7%)
Other (Not Including Serious) Adverse Events
	Cohort A
	Affected / at Risk (%)	# Events
Total	6/6 (100%)
Blood and lymphatic system disorders
Anaemia	4/6 (66.7%)
Cardiac disorders
Mitral valve incompetence	1/6 (16.7%)
Ear and labyrinth disorders
Deafness unilateral	1/6 (16.7%)
Eye disorders
Ocular hypertension	1/6 (16.7%)
Photopsia	1/6 (16.7%)
Vision blurred	1/6 (16.7%)
Gastrointestinal disorders
Constipation	2/6 (33.3%)
Diarrhoea	2/6 (33.3%)
Nausea	2/6 (33.3%)
Mouth ulceration	1/6 (16.7%)
Oral pain	1/6 (16.7%)
Stomatitis	1/6 (16.7%)
Vomiting	1/6 (16.7%)
General disorders
Fatigue	4/6 (66.7%)
Pyrexia	4/6 (66.7%)
Chills	2/6 (33.3%)
Non-cardiac chest pain	1/6 (16.7%)
Oedema peripheral	1/6 (16.7%)
Pain	1/6 (16.7%)
Infections and infestations
Candida infection	1/6 (16.7%)
Oral herpes	1/6 (16.7%)
Injury, poisoning and procedural complications
Procedural pain	3/6 (50%)
Investigations
Blood lactate dehydrogenase increased	3/6 (50%)
Lymphocyte count decreased	3/6 (50%)
Blood alkaline phosphatase increased	2/6 (33.3%)
Lipase increased	2/6 (33.3%)
Amylase increased	1/6 (16.7%)
Aspartate aminotransferase increased	1/6 (16.7%)
Blood creatine phosphokinase increased	1/6 (16.7%)
Blood creatinine increased	1/6 (16.7%)
Neutrophil count decreased	1/6 (16.7%)
Platelet count decreased	1/6 (16.7%)
Weight decreased	1/6 (16.7%)
White blood cell count decreased	1/6 (16.7%)
Metabolism and nutrition disorders
Hyponatraemia	4/6 (66.7%)
Hypokalaemia	3/6 (50%)
Hypophosphataemia	3/6 (50%)
Decreased appetite	1/6 (16.7%)
Dehydration	1/6 (16.7%)
Glucose tolerance impaired	1/6 (16.7%)
Hyperkalaemia	1/6 (16.7%)
Hypoalbuminaemia	1/6 (16.7%)
Hypocalcaemia	1/6 (16.7%)
Hypochloraemia	1/6 (16.7%)
Hypoglycaemia	1/6 (16.7%)
Hypomagnesaemia	1/6 (16.7%)
Musculoskeletal and connective tissue disorders
Myalgia	2/6 (33.3%)
Arthralgia	1/6 (16.7%)
Back pain	1/6 (16.7%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis	1/6 (16.7%)
Nervous system disorders
Headache	3/6 (50%)
Dysgeusia	1/6 (16.7%)
Seizure	1/6 (16.7%)
Psychiatric disorders
Confusional state	1/6 (16.7%)
Insomnia	1/6 (16.7%)
Renal and urinary disorders
Pollakiuria	1/6 (16.7%)
Proteinuria	1/6 (16.7%)
Respiratory, thoracic and mediastinal disorders
Cough	2/6 (33.3%)
Dry throat	1/6 (16.7%)
Dysphonia	1/6 (16.7%)
Oropharyngeal pain	1/6 (16.7%)
Skin and subcutaneous tissue disorders
Pruritus	3/6 (50%)
Actinic keratosis	2/6 (33.3%)
Dermatitis acneiform	2/6 (33.3%)
Rash	2/6 (33.3%)
Hyperhidrosis	1/6 (16.7%)
Night sweats	1/6 (16.7%)
Rash pruritic	1/6 (16.7%)
Vascular disorders
Hypotension	1/6 (16.7%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.